Oyegunwa Akinbolade 4

What Happened Oyegunwa Akinbolade, EVP, Chief Information & Technology Officer of Labcorp Holdings, received equity awards on February 10, 2026: 2,400 employee stock options and 810 restricted stock units (RSUs). The Form 4 reports an acquisition price of $0 for both items (typical for reported grants). The options give the right to buy shares under the Labcorp 2025 Omnibus Incentive Plan; the RSUs represent a contingent right to receive shares if vesting conditions are met. These are grants (compensation), not open-market purchases or sales.

Key Details

• Transaction date: February 10, 2026. Form filed: February 12, 2026 — appears timely (within 2 business days).
• Grants: 2,400 employee stock options (derivative), acquisition price $0; 810 RSUs, acquisition price $0.
• Vesting: Options vest in three equal annual installments beginning on the date reflected in the filing (per F2). RSUs vest in three equal annual installments beginning February 10, 2027 (per F4).
• Footnotes: F1 = options granted under Labcorp 2025 Omnibus Incentive Plan; F3 = each RSU equals the right to one share; F5 notes the RSU number reflects the reporting person's aggregate RSUs.
• Shares owned after the transaction: not disclosed in the provided filing details.
• No sale or exercise occurred — no proceeds or cashless exercise reported.

Context These awards are standard executive compensation — options provide the right to buy stock in the future and RSUs convert to shares as they vest. Awards themselves are routine and do not necessarily signal immediate insider buying or selling. Retail investors should view this as a compensation grant with multi-year vesting rather than an outright purchase or disposition.